KOREA-US

Frontiers in Health and Life Sciences

2025. 11. 6(Thu) - 7(Fri)

Four Seasons Hotel, Grandballroom(3F)

Curriculum Vitae

Name	**First Name**	Jeonghee	**Last Name**	Cho
Country	Republic of Korea			
Affiliation	Dankook University			

Educational Background	
2011	**Post-doctoral fellow,** Dept. of Medical Oncology, Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, Boston, USA
2005	**Ph.D.,** Dept. of Molecular Genetics, Tufts Univ., Boston, USA
1997	**B.S.,** Dept. of Biological Science, SungKyunKwan Univ., Korea

Professional Career	
2015- present	**Professor,** Dept. of Biomedical Sciences & Biosystems, Dankook University
2025	**Vice President**, The Genetics Society of Korea
2025	**Vice President**, Korean Society for Integrative Biology
2024- present	**Director,** International Consortium for Development of Innovative anti-Cancer Drugs
2023- present	**Editor**, Genes and Genomics
2022- present	**Director,** DKU-LigaChemBio Innovative Anti-Cancer Drug Research Institute
2021- 2024	**Director,** DKU-HANMI Innovative Drug Research Center
2013- 2015	**Adjunct Assistant Professor,** Samsung Advanced Institute for Health Science & Technology (SAIHST)
2011- 2015	**Principal Investigator**, Samsung Medical Center

Research Field
Innovative anti-cancer drug development through mechanistic insights and genomic approaches.

Papers, Books, etc. presented or published by your name

1. **Selected publications**
   a. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6, *Nature Structural & Molecular Biology*
   b. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. *Cancer Research*
   c. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*
   d. Cetuximab response of lung cancer–derived EGF receptor mutants is associated with asymmetric dimerization. *Cancer Research,*
   e. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. *Molecular Cancer.*
   f. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. *International Journal of Cancer*

2. **Selected patents**
   a. EGFR molecular targeted therapy resistance-inducing markers and their applications
   b. Composition for inhibiting anticancer drug resistance following EGFR-targeted therapy withdrawal
   c. Pharmaceutical composition for treating EGFR-targeted therapy-resistant cancer
   d. Pharmaceutical composition for overcoming resistance to EGFR-targeted cancer therapy
   e. Molecule for predicting EGFR-targeted therapy resistance and screening method for EGFR-targeted therapy resistance-inhibiting drugs